Literature DB >> 3164387

Effects of N-deacetylation and N-desulfation of heparin on its anticoagulant activity and in vivo disposition.

T D Bjornsson1, D E Schneider, A R Hecht.   

Abstract

This investigation compares the anticoagulant activities and in vivo disposition characteristics of N-deacetylated heparin and N-desulfated heparin with those of standard heparin in an animal model. The N-deacetylated heparin retained 23% of the anticoagulant activity, 34% of the anti-Xa activity and 23% of the anti-IIa activity of standard heparin, whereas the N-desulfated heparin retained only 1.5% of the anticoagulant activity, 0.095% of the anti-Xa activity and 0.92% of the anti-IIa activity of the original heparin. After i.v. injections of 5 mg/kg of the modified heparins, both N-deacetylated and N-deacetylated heparin concentrations showed monoexponential declines with time. The elimination half-lives were similar, 11.7 +/- 3.8 and 13.5 +/- 5.2 min, respectively (N.S.). There were, however, significant differences in both total clearance (Cl) and apparent volume of distribution (Vd) for these heparins, both parameters being significantly larger for the N-deacetylated heparin (P = .0007). The Cl values were 4.15 +/- 1.11 and 0.58 +/- 0.26 ml/min/kg and the Vd values were 72.1 +/- 38.7 and 9.9 +/- 2.4 ml/kg for the N-deacetylated and N-desulfated heparins, respectively. We have reported previously that after a similar dose of standard heparin the elimination half-life was 69.0 +/- 13.1 min, Cl was 0.64 +/- 0.16 ml/min/kg and Vd was 62.6 +/- 16.7 ml/kg. These studies have thus demonstrated that selective N-deacetylation and N-desulfation of the glucosamine residues of heparin affect markedly both its anticoagulant activity and in vivo disposition characteristics. Although important for full anticoagulant activity of heparin, the N-acetyl groups are apparently not essential.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3164387

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  8 in total

Review 1.  Antiplatelet drugs: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

Authors:  John W Eikelboom; Jack Hirsh; Frederick A Spencer; Trevor P Baglin; Jeffrey I Weitz
Journal:  Chest       Date:  2012-02       Impact factor: 9.410

2.  Endocytotic routes of cobra cardiotoxins depend on spatial distribution of positively charged and hydrophobic domains to target distinct types of sulfated glycoconjugates on cell surface.

Authors:  Shao-Chen Lee; Chien-Chu Lin; Chia-Hui Wang; Po-Long Wu; Hsuan-Wei Huang; Chung-I Chang; Wen-guey Wu
Journal:  J Biol Chem       Date:  2014-06-04       Impact factor: 5.157

3.  Anti-angiogenic poly-L-lysine dendrimer binds heparin and neutralizes its activity.

Authors:  Khuloud T Al-Jamal; Wafa T Al-Jamal; Kostas Kostarelos; John A Turton; Alexander T Florence
Journal:  Results Pharma Sci       Date:  2011-12-08

Review 4.  The quest for non-invasive delivery of bioactive macromolecules: a focus on heparins.

Authors:  Nusrat A Motlekar; Bi-Botti C Youan
Journal:  J Control Release       Date:  2006-06-14       Impact factor: 9.776

5.  Effect of N-desulfated heparin on hepatic/renal ischemia reperfusion injury in rats.

Authors:  Tong Zhou; Jin-Lian Chen; Wei Song; Feng Wang; Ming-Jun Zhang; Pei-Hua Ni; Jian-Guo Geng
Journal:  World J Gastroenterol       Date:  2002-10       Impact factor: 5.742

Review 6.  Heparin pharmacokinetics and pharmacodynamics.

Authors:  R J Kandrotas
Journal:  Clin Pharmacokinet       Date:  1992-05       Impact factor: 6.447

7.  Is GERD a Factor in Osteonecrosis of the Jaw? Evidence of Pathology Linked to G6PD Deficiency and Sulfomucins.

Authors:  Stephanie Seneff; Nancy L Swanson; Gerald Koenig; Chen Li
Journal:  Dis Markers       Date:  2016-09-28       Impact factor: 3.434

8.  Optimization of experimental parameters for the production of LMWH-loaded polymeric microspheres.

Authors:  Nusrat Motlekar; Bi-Botti Youan
Journal:  Drug Des Devel Ther       Date:  2009-02-06       Impact factor: 4.162

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.